Cancer Family
Malignant Nervous System Neoplasm
CI-CAN-00000246Explore in graph →
954 active trials7 approved drugs131 evidence items
- NCIt
- C4788
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000246Explore in graph →
Clinical trials
3,459 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (494)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07789379 | Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma | not yet recruiting | Phase 2 | 94 | Wei JiangOTHER | 0 | Aug 27, 2026 | clinicaltrials |
| NCT07789938 | Intraoperative Neurophysiological Monitoring in Brain Tumor Surgery: Prospective Cohort Studies | not yet recruiting | N/A | 166 | Odense University HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07791264 |
| FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma |
| not yet recruiting |
| Phase 1 |
| 24 |
| City of Hope Medical CenterOTHER |
| 1 |
| Aug 27, 2026 |
| clinicaltrials |
| NCT05219149 | CNS Qualitative Interview | completed | — | 17 | University of Colorado, DenverOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05236036 | Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma | active not recruiting | Phase 1 | 86 | Northwestern UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05857969 | Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling | recruiting | Phase 1 | 65 | Florida International UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06557512 | Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma(SRS-AIM) | recruiting | N/A | 23 | University of California, San FranciscoOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06701812 | Digoxin Medulloblastoma Study | recruiting | Phase 2 | 23 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07778602 | Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas | not yet recruiting | Early Phase 1 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Aug 26, 2026 | clinicaltrials |
| NCT07788430 | Impact of Pesticide Exposure on Survival and Tumor Aggressiveness in Patients With Glioblastoma: A Prospective Clinical Study(EXPOGLIO) | not yet recruiting | N/A | 120 | Institut Claudius RegaudOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02176967 | Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma | active not recruiting | Phase 3 | 621 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT03126916 | Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | recruiting | Phase 3 | 750 | Children's Oncology GroupNETWORK | 3 | Aug 25, 2026 | clinicaltrials |
| NCT03959085 | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | recruiting | Phase 3 | 5,951 | Children's Oncology GroupNETWORK | 5 | Aug 25, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05039281 | Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05382338 | A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | recruiting | Phase 3 | 225 | Children's Oncology GroupNETWORK | 2 | Aug 25, 2026 | clinicaltrials |
| NCT05504291 | A Study to Give Treatment Inside the Eye to Treat Retinoblastoma | recruiting | Phase 2 | 26 | Children's Oncology GroupNETWORK | 3 | Aug 25, 2026 | clinicaltrials |
| NCT06368817 | A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | recruiting | Phase 2 | 240 | Children's Oncology GroupNETWORK | 3 | Aug 25, 2026 | clinicaltrials |
| NCT07076472 | Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma | recruiting | Early Phase 1 | 8 | Mayo ClinicOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07579208 | A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma | recruiting | Phase 1 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT03170141 | Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme | terminated | Phase 1 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04214392 | Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma | active not recruiting | Phase 1 | 19 | City of Hope Medical CenterOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05096481 | PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma | recruiting | Phase 2 | 120 | Nationwide Children's HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05253131 | Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas | recruiting | Phase 2 | 41 | University of Alabama at BirminghamOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05463848 | Surgical Pembro +/- Olaparib w TMZ for rGBM | active not recruiting | Phase 2 | 52 | L. Nicolas Gonzalez Castro, MD, PhDOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06954636 | Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study(OLFGBM) | recruiting | — | 128 | Sied KebirOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07635056 | Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma | recruiting | Phase 2 | 20 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04106219 | A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma | active not recruiting | Phase 1 | 71 | Eli Lilly and CompanyINDUSTRY | 9 | Aug 21, 2026 | clinicaltrials |
| NCT05701306 | APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07209241 | Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM | active not recruiting | Phase 1 | 12 | University of PennsylvaniaOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07261241 | NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab | not yet recruiting | Phase 2 | 118 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07485049 | BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors | recruiting | Early Phase 1 | 78 | Nader SanaiOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07608731 | Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas | not yet recruiting | Phase 1 | 18 | Allison WinterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07767630 | Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma | recruiting | Early Phase 1 | 10 | Sichuan UniversityOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07778940 | Thiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI.(LEP-THP-2026) | not yet recruiting | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT00268385 | Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas | active not recruiting | Phase 1 | 83 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2026 | clinicaltrials |
| NCT02112617 | Phase II Study of Proton Radiation Therapy for Neuroblastoma | active not recruiting | N/A | 30 | Massachusetts General HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT02282735 | Parental Decision-Making for Children With Relapsed Neuroblastoma | active not recruiting | — | 96 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT02658279 | Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype | active not recruiting | N/A | 27 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07775534 | Tear Fluid for the Detection of Tumor-associated Extracellular Vesicles in Glioblastoma Patients | not yet recruiting | N/A | 30 | City of Hope Medical CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT00918320 | Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours(TOTEM2) | completed | Phase 2 | 129 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT02977780 | INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) | recruiting | Phase 2 | 460 | David Reardon, MDOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03025256 | Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease | active not recruiting | Phase 1 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05036577 | A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL(ORMD2021) | completed | Phase 1 | 13 | Huashan HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06108206 | Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma | active not recruiting | — | 20 | Columbia UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06556563 | EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma(EF-41) | recruiting | Phase 3 | 741 | NovoCure GmbHINDUSTRY | 12 | Aug 19, 2026 | clinicaltrials |
| NCT07185373 | Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL | recruiting | Phase 2 / Phase 3 | 215 | Huashan HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07660458 | Parental Distress and Treatment Adherence in Pediatric Recurrent Medulloblastoma | withdrawn | — | 0 | West China HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07762716 | Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy | not yet recruiting | Phase 1 / Phase 2 | 10 | BreakBio CorpINDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03173950 | Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers | terminated | Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Aug 27, 2026source: clinicaltrials